Q-omics provides the consensus-scored TAS2R14 profile across patient tissues and cancer cell-line models. TAS2R14 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TAS2R14 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, TAS2R14 RNA expression shows 20,861 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where TAS2R14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAS2R14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAS2R14 survival associations across molecular data types. TAS2R14 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAS2R14 RNA expression–survival associations across cancer types. High TAS2R14 expression shows unfavorable associations in KIRC, ACC, STAD, DLBC and UVM, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TAS2R14 RNA expression.
This table summarizes TAS2R14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TAS2R14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAS2R14 shows lower tumor expression in THCA, UCEC and KICH and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher TAS2R14 RNA expression in tumor versus normal tissue (log2 FC = +0.297, t-test p < 0.001).
This table shows molecular features associated with TAS2R14 in patient tissues and cancer cell lines. In patient samples, TAS2R14 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAS2R14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
